Krystal Integrated wins Rs 12.83 crore housekeeping contract for Maha Mumbai Metro Lines 2A and 7
The contract includes housekeeping of 34 metro trains, the Charkop Depot, three Receiving Substations (RSS), and the key simulator buildings at Mandale Depot. It spans across Metro Line 2A (Andheri West to Dahisar East) and Line 7 (Gundavali to Ovaripada), two critical corridors of the city's metro network.
Advertisement
Sanjay Dighe, CEO and Whole Time Director at Krystal, stated, 'This project reinforces Krystal's proven track record in maintaining large-scale infrastructure. It adds Mumbai's urban mobility mission to our portfolio and strengthens our commitment to public service.'
Krystal's responsibilities extend beyond just cleanliness—they play a key role in ensuring hygienic and safe journeys for millions of commuters every day. The company is known for managing complex operations across key sectors like healthcare, aviation, education, public administration, airports, and retail.
In addition to facility services, KISL also offers private security, payroll and staffing solutions, catering, and has been expanding into solid and liquid waste management, along with operations and maintenance (O&M) services.
With this metro project, Krystal continues to cement its position as a trusted partner in India's infrastructure and urban management ecosystem.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
7 days ago
- Forbes
How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease'
L ongtime drug developer Suma Krishnan was in her late-40s when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder in which the skin becomes as fragile as butterfly wings. In 2016, at 51, after a few months of modeling the idea and starting the process of patenting it, she and her husband Krish Krishnan, with whom she'd worked in biotech for more than a decade, cofounded Krystal Biotech. Focusing on a rare disease, with just thousands of patients in the U.S., was unusual. So, too, was shunning venture capital in favor of self-funding a biotech startup, with some $5 million they'd made mainly from previous biotech companies. But perhaps the biggest bet was the science, taking a completely new approach to a problem with a gene therapy delivered as a gel that would potentially pay off big if it succeeded, but also stood a high chance of failure. 'I had to work with the regulators because they had never seen this,' Krishnan told Forbes . 'It was completely new.' Just 18 months after launching the Pittsburgh-based company, the Krishnans took it public on the Nasdaq stock exchange. Today, Krystal has a market cap of $4.4 billion with one FDA-approved therapy, Vyjuvek, for that "butterfly skin disease,"called dystrophic epidermolysis bullosa, on the market, and other gene therapies, including for cystic fibrosis and lung cancer, in various stages of clinical development. All rely on the modified herpes simplex virus, but they have different delivery mechanisms. The company's revenue reached $291 million for 2024, up more than five-fold from $51 million in 2023. Net income surged eightfold to $89 million from $11 million in the same period. The Krishnans have a combined 12% stake in the business. Suma, the company's president of research and development, is worth some $300 million by Forbes estimates, almost entirely from her stake in the business and sales of stock over the years. Krystal's stock has been volatile: It's up more than 1,300% since the IPO, but has fallen nearly 25% over the past year. 'You have to be brave and bold to do this,' Krishnan says. 'I was never afraid of risk-taking. I never felt like I needed a stable job.' Krishnan is one of the 200 entrepreneurs and leaders on this year's Forbes' 50 Over 50 list. These women—who this year also include actress Halle Berry, on the list for her menopause-related startup; social mission-oriented investor Freada Kapor Klein; and Maria Shriver, who founded the Women's Alzheimer's Movement toward the end of her first term as first lady of California—are all generating outsized professional impact in their sixth, seventh or eighth decades. Suma Krishnan, who is now 60, grew up in Bombay where her parents struggled to raise three kids. As the middle child and a girl, Krishnan says, her mother, who married at 18, began looking for arranged marriages for her as soon as she finished college. She refused. 'I always defied it and fought it,' she says. 'I was a tough one for them. I broke all the rules.' She came to the U.S. for graduate school, getting a master's degree in organic chemistry at Villanova University. (While there, she met Krish Krishnan, who was getting his MBA at Wharton and lived nearby.) After that, she worked as a drug developer, starting at Janssen Pharmaceuticals. At New River Pharmaceuticals, she led the discovery, development and approval of Vyvanse, a blockbuster drug to treat ADHD. After European drugmaker Shire (acquired by Takeda for $62 billion in 2018) bought New River for $2.6 billion in 2007, she worked on rare diseases. Then, at Intrexon (now known as Precigen), she focused on gene therapy treatments as its head of therapeutics. She holds more than 70 patents for a variety of drugs. 'For 25, 30 years, this is all that I did,' she says. 'I am familiar with all kinds of rare diseases and where the unmet need is.' 'I was never afraid of risk-taking. I never felt like I needed a stable job.' Krystal Biotech cofounder Suma Krishnan She had an idea for a gene therapy for butterfly skin patients that could be delivered as a gel directly onto the affected skin using a modified version of the herpes simplex virus to deliver the treatment. The drug works by delivering a healthy copy of the gene that encodes a type of collagen to the skin cells, enabling healing to occur. Some 25,000 people in the United States have epidermolysis bullosa, but only around 3,000 of them have the dystrophic form of it, which is severe and for which Krystal's treatment is used. Brett Kopelan, executive director of Debra, a nonprofit for those affected by the disease, and whose daughter, now 17, was born with a severe form of it, calls it 'the worst f—-ing disease you've never heard of.' Kids with it often live with constant pain and need to be bandaged on much of their bodies; they're also susceptible to numerous other ailments, including a form of skin cancer. 'My goal is to make this a chronic, livable disease like type 2 diabetes,' says Kopelan, whose daughter uses Krystal's treatment, among others. 'We're getting really close to that, and we have Suma and Krish to thank.' When she had the idea that became Vyjuvek, there were no treatments on the market. While she was at Intrexon, that company had been working with another biotech, Fibrocell (which has since been purchased by Castle Creek), on a hospital-based therapy. 'I saw the pain and suffering,' Krishnan says. 'These kids are born with missing skin from birth and it gets worse over time. They say, 'Nobody cares about us.'' She took the idea to her husband Krish, who had been the chief operating officer at New River and Intrexon and with whom she had worked for well over a decade. They decided to develop the drug—this time on their own. Biotech was booming and lab space was impossible to find in San Francisco. Instead, they searched the country for locations, settling up in a vacant lab space in Pittsburgh, a city known more for robotics startups than biotech but where they could hire grad students from Carnegie Mellon, at first flying back and forth from their home in northern California. They shunned VC funding, raising a small amount from friends and family and telling them bluntly to think of their investment as philanthropy. 'We figured if it didn't work out, we'd shut it down,' Krishnan says. In 2017, they took the company public, raising $45 million, thanks to Krish Krishnan's network taking previous companies through their IPOs. 'It was a Mickey Mouse IPO,' he says, noting that it allowed an investor from Fidelity who'd backed his previous companies to become a shareholder. 50 Over 50: 2025 Our fifth annual list of 200 women who are redefining what's possible in life's second half. VIEW THE FULL LIST The idea of delivering gene therapy at home rather than in the hospital was both elegant and a little crazy. 'Look, honestly, as great as the idea was, when somebody comes and says, 'I want to put gene therapy in a gel on a wound at home,' it's like somebody saying today, 'I want to have a house on Mars,'' says Krish Krishnan, the company's CEO. 'Yeah, great idea, but how are you going to get there? It was that kind of idea.' Six years later, in 2023, Krystal received FDA approval for Vyjuvek—very fast for a novel gene therapy. Getting the FDA to sign off on a home-based gene therapy that would use a modified version of the herpes virus during the Covid-19 pandemic required studies that could allay any concerns about safety at a time when, as Krishnan notes, 'people were very nervous about viruses.' They set a list price of $24,250 per vial. That works out to an annual cost of $631,000 per year for an average patient who uses 26 vials, before discounts; but patients typically require fewer treatments over time as their wounds heal. Gene therapies tend to be expensive, with many costing $1 million or more. With rare disease, 'the payers are a bit more forgiving on the pricing,' Krish Krishnan says, noting that any one insurer is unlikely to have more than a few patients with the disease. 'We can show the value proposition to Blue Cross Blue Shield and they understand,' he says. Life sciences investor Dan Janney, managing partner of Alta Partners, was among the few friends who invested personally in Krystal in the early days, having met Suma and Krish through their children, who went to school together. He calls Krystal 'probably the most efficient company that I've ever been involved in' in terms of its use of capital. 'They've done a really incredible job of getting to profitability,' he says. 'As great as the idea was, when somebody comes and says, 'I want to put gene therapy in a gel on a wound at home,' it's like somebody saying today, 'I want to have a house on Mars.' Krystal Biotech cofounder Krish Krishnan Krystal's drug for the butterfly skin disease isn't the only one on the market anymore. In April, clinical-stage biotech Abeona Therapeutics (which is publicly traded with a market cap of $348 million) gained FDA approval for its own gene therapy, called Zevaskyn, which uses skin grafts from sheets of a genetically modified version of the patient's own skin cells. That treatment, which has a list price of $3.1 million, launched this summer. Having gotten the one therapy on the market in the U.S. and approval for it in Europe and Japan, Krishnan is now looking at other diseases in lung disease, cancer and eye ailments. One of the furthest along, now in phase 3 clinical studies, is for ocular complications of the skin disease they're already treating. Others, now in earlier stage clinical trials, include treatments for cystic fibrosis and for lung tumors, a particular focus of Krishnan's given the increasing prevalence of lung cancer among younger women who never smoked. In each case, Krystal's drug would deliver a healthy copy of the gene to treat the disease, though the delivery mechanisms vary, with the lung cancer therapy using a nebulizer, for example. The big question is whether Krystal can successfully expand beyond one rare disease to multiple drugs that can treat a variety of health problems using gene therapies delivered with the modified herpes virus. Krishnan's plan is to use the cash from Vyjuvek's commercial sales to fund the clinical development of those other therapies. 'We have money and we can use that to develop the rest of our pipeline products,' she says. 'The first one is always harder.' More from Forbes Forbes This AI Founder Became A Billionaire By Building ChatGPT For Doctors By Amy Feldman Forbes Meet India's Self-Made Biologics Brewmaster Billionaire By Amy Feldman Forbes How Halle Berry Became The New Face Of Menopause By Maggie McGrath Forbes How This Founder Turned A Crocs-Inspired Tote Into A $100 Million Business By Lindsey Choo
Business Upturn
14-07-2025
- Business Upturn
Cryptosolo Launches Next-Generation Cloud Mining in 2025, Making Secure Passive Crypto Income Easy
By GlobeNewswire Published on July 14, 2025, 21:59 IST London, UK, July 14, 2025 (GLOBE NEWSWIRE) — Against the backdrop of the continuous growth of global digital assets, cloud mining has become an increasingly popular choice for investors and crypto enthusiasts seeking passive income. Today, the newly upgraded Cryptosolo cloud mining platform is officially launched, dedicated to providing global users with a safer, more efficient, and user-friendly experience for earning passive crypto income. As global demand for accessible and environmentally friendly crypto mining continues to grow, Cryptosolo is expanding its influence through enhanced smart mining technology, clean energy operations, and flexible investment packages to meet the needs of both beginners and experienced users can immediately register at and receive a $15 welcome bonus, activating their first mining contract with no initial Krystal, spokesperson for Cryptosolo, said: 'We are excited to open a new chapter for Cryptosolo, providing people with an intuitive, secure, and transparent way to earn cryptocurrency every day. Our platform uses AI configuration and renewable energy to offer a worry-free source of income for anyone, whether they are casual investors or actively managing portfolios on platforms like Robinhood.' Highlights of the New Cryptosolo Platform Instant Start, No Equipment Needed Cryptosolo makes mining simple—users register, choose a plan, and start earning daily crypto rewards without any maintenance or technical skills. Green, Low-Carbon Mining All mining farms are powered by renewable energy, including wind, hydro, and solar, reducing environmental impact while ensuring uninterrupted performance. Smart AI Allocation Cryptosolo's intelligent system efficiently allocates computing resources, guaranteeing stable daily returns for thousands of users worldwide. Customizable Mining Packages Flexible contract prices—from $200 up to $60,000—allow users to adjust mining profits based on their budget and goals. For full package details, please visit the official website. Rapid Global Adoption With over 8 million users in North America, Asia, and Europe, Cryptosolo is continuously expanding its global presence while adhering to strict compliance standards. Simple Steps to Start Mining with Cryptosolo1、 Register for free and claim your $15 bonus2、 Choose a mining plan that fits your investment strategy3、 Earn daily income automatically4、 Withdraw profits securely at any tim Click here to learn more about the project. For more information about contract options, security features, and user testimonials, please visit the website. About Cryptosolo Cryptosolo is a new-generation leader in cloud mining based in the UK, committed to providing reliable, clean energy-driven mining services so everyone can earn passive crypto income. Through advanced AI allocation and robust security systems, Cryptosolo offers a worry-free mining experience with no hidden fees or technical barriers. Media Inquiries:Cryptosolo Email:[email protected] Website: Disclaimer: The information provided in this press release is not intended as investment advice, financial advice, or trading advice. Cryptocurrency mining and staking involve risk, and there is potential for loss of funds. We strongly recommend conducting your own due diligence and consulting with a licensed financial advisor before making any investment decisions related to cryptocurrencies or securities. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
08-07-2025
- Business Wire
Mobileye Announces Timing of its Second Quarter 2025 Results
JERUSALEM--(BUSINESS WIRE)--Mobileye Global Inc. (Nasdaq: MBLY) ('Mobileye') today announced that it will release its financial results for the second quarter 2025 on Thursday July 24th, 2025, before market open. Mobileye will host a conference call at 8:00 a.m. ET (3:00 p.m. IT) to review its results and provide a general business update. The call will be hosted by Professor Amnon Shashua, CEO, Moran Shemesh Rojansky, CFO, Nimrod Nehushtan, EVP – Business Development and Strategy, and Dan Galves, CCO. The conference call will be accessible live via a webcast on Mobileye's investor relations site, which can be found at and a replay of the webcast will be made available shortly after the event's conclusion. About Mobileye Global Inc. Mobileye (Nasdaq: MBLY) leads the mobility revolution with our autonomous driving and driver-assistance technologies, harnessing world-renowned expertise in artificial intelligence, computer vision, mapping and integrated software and hardware. Since our founding in 1999, Mobileye has enabled the wide adoption of advanced driver-assistance systems that bolster driving safety, while pioneering such groundbreaking technologies as REM™ crowdsourced mapping, True Redundancy™ sensing, and Responsibility Sensitive Safety™ (RSS). These technologies drive the ADAS and AV fields towards the future of mobility – enabling self-driving vehicles and mobility solutions at scale, and powering industry-leading advanced driver-assistance systems. Through 2024, more than 200 million vehicles worldwide have been built with Mobileye's EyeQ ™ technology inside. Since 2022, Mobileye has been listed independently from Intel (Nasdaq: INTC), which retains majority ownership. For more information, visit 'Mobileye,' the Mobileye logo and Mobileye product names are registered trademarks of Mobileye Global. All other marks are the property of their respective owners.
